What is Oxytocin?
Oxytocin is a peptide hormone used in supervised obstetric care. Its established clinical context should be separated from popular social or wellness claims.
Biological role or research focus
Uterine contraction in obstetric care.
Clinical obstetric uses do not establish online claims about bonding, mood, or sexual enhancement.
Role reference: MedlinePlus · Oxytocin ↗
- Class / identity
- Oxytocic hormone
- Main research area
- Obstetric care
- Evidence featured
- Human randomized trial
- Source check
- October 4, 2026
Source: MedlinePlus · Oxytocin ↗
Quick answers
- Is Oxytocin FDA approved?
- Yes. Pitocin (NDA 018261) and generic oxytocin injection to induce or strengthen labor and control postpartum bleeding. Source ↗
- Is Oxytocin safe?
- Oxytocin (Pitocin) is a hospital-only labor drug; too much can overstimulate or rupture the uterus, cause dangerous water intoxication and harm the baby. Human safety data: its FDA label lists the known risks. The Risks & interactions section below lists what is known. Read the risks ↓
- Is Oxytocin banned in sport?
- It is not named on the 2026 World Anti-Doping Agency (WADA) Prohibited List. Athletes should still check with their sport’s anti-doping body. Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| Route comparison after vaginal birth (2018) | Human randomized trial | 1,075 women randomized; 1,035 included in analyses at an Irish maternity unit. |
| SOARS-B · intranasal oxytocin (2021) | Human phase 2 randomized trial | 290 participants aged 3–17; 277 contributed to the modified intention-to-treat analysis. |
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human randomized trial · 2018
Route comparison after vaginal birth
Intramuscular versus intravenous oxytocin to prevent postpartum haemorrhage at vaginal delivery: randomised controlled trial.
- Population / model
- 1,075 women randomized; 1,035 included in analyses at an Irish maternity unit.
- Study design
- Intravenous versus intramuscular oxytocin with matching placebo injections.
- Main finding
- The primary bleeding endpoint was not significantly different. Severe postpartum bleeding, a secondary endpoint, occurred in 4.6% versus 8.1%, favoring intravenous administration.
- Limits & context
- Both groups received oxytocin under clinical supervision. This addresses route selection after delivery, not bonding, mood, or unsupervised nasal-spray use.
Human phase 2 randomized trial · 2021
SOARS-B · intranasal oxytocin
Did social functioning improve in children and adolescents with autism?
- Population / model
- 290 participants aged 3–17; 277 contributed to the modified intention-to-treat analysis.
- Study design
- 24-week placebo-controlled intranasal trial, stratified by age and verbal fluency.
- Main finding
- The primary social-withdrawal score changed by −3.7 versus −3.5 points; difference −0.2 (95% CI −1.5 to 1.0), P=0.61. Secondary outcomes generally did not differ. Adverse-event frequency and severity were similar.
- How to read it
- The larger trial did not show benefit on its measured social or cognitive outcomes.
- Limits & context
- These results concern the studied population, formulation, and duration. They do not establish a general bonding or cognitive-enhancement effect, nor determine outcomes in every other clinical setting.
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
67 registered studies name Oxytocin as an intervention among the 100 most recently updated of 938 search results; 34 are recruiting or under way, 12 have not started recruiting yet, 15 completed and 6 ended early, were withdrawn or have another status. Checked November 16, 2026 on ClinicalTrials.gov.
A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination. All 67 listed studies.
Search additional PubMed records ↗Risks & interactions
Oxytocin (Pitocin) is a hospital-only labor drug; too much can overstimulate or rupture the uterus, cause dangerous water intoxication and harm the baby.
Not approved for elective induction of labor (starting labor without a medical reason), because the available data are not enough to weigh the benefits against the risks.
Safety is established by FDA labeling and long hospital use in labor and after delivery. The label lists reactions without frequencies, and states that data are inadequate to judge elective induction. It is given only under hospital supervision.
Take extra care with: Heart or blood pressure problemsPregnancy or breastfeeding
From the FDA label lists below. If a condition applies to you, talk to a doctor or pharmacist first. Each tag opens every profile that mentions it.
Who should not use it
- Baby cannot safely pass through the pelvis, or is in a position that cannot be delivered
- Fetal distress when delivery is not about to happen
- Uterus already overactive or contracting too strongly
- When vaginal delivery is unsafe, such as placenta previa, cord prolapse or active genital herpes
- Obstetric emergencies that favor surgical delivery
- Allergy to oxytocin
Interactions
- Vasoconstrictors given with caudal block anesthesia: severe high blood pressure has been reported
- Cyclopropane anesthesia: can cause low blood pressure and abnormal heart rhythms in the mother
Serious risks
- Overly strong contractions and rupture of the uterus
- Water intoxication with seizures, coma or death
- Heavy bleeding after delivery and fatal loss of clotting protein (afibrinogenemia)
- Severe allergic reactions
- Irregular heartbeat and episodes of high blood pressure in the mother
- Harm to the baby, including slow heart rate, seizures, brain damage or death
Common side effects
- nausea
- vomiting
Summarized from the FDA label with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: DailyMed: Pitocin (oxytocin) prescribing information ↗
Key precautions
Excessive uterine stimulation and other serious complications require monitoring by the maternity team. Prior uterine surgery, fetal position, and placental conditions can affect suitability.
Source: MedlinePlus · Oxytocin ↗
Regulatory status
- U.S. FDA approval
- Approved
Pitocin (NDA 018261) and generic oxytocin injection to induce or strengthen labor and control postpartum bleeding. source - FDA compounding (503A bulk list)
- Not on FDA’s compounding lists
Not on FDA's 503A nominated-substance category lists. As a component of an FDA-approved drug it does not need to be on the 503A bulks list to be used in pharmacy compounding (other 503A conditions still apply). source - World Anti-Doping Agency (2026)
- Not on the WADA Prohibited List
Not named and not within a prohibited class on the 2026 List. source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Clinical uses & product context
The medication reference describes initiating or strengthening labor contractions and reducing bleeding after childbirth. Clinical circumstances, fetal status, and obstetric contraindications guide its use.
Source: MedlinePlus · Oxytocin ↗
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
This is a prescription medicine, available only with a prescription through a pharmacy. Versions sold online as "research" products are not the approved medicine, and the FDA has warned sellers of them, so PepsRadar does not list, compare or link them. See the official product information linked in References.
Mechanism & research rationale
It stimulates uterine contractions. That action explains labor-related and postpartum uses but does not establish a predictable improvement in bonding or mood.
Source: MedlinePlus · Oxytocin ↗
Molecular structure
Questions worth asking
- Which indication and formulation does the source describe?
- Does the video make a broader claim than the source supports?
- Clinical obstetric uses do not establish online claims about bonding, mood, or sexual enhancement.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Video & podcast discussions: members library
Frequently asked questions
Does an obstetric trial validate a bonding nasal spray?
No. Route, population, and outcome all differ.
Source: MedlinePlus · Oxytocin ↗
Did the route-comparison study show every bleeding outcome improved?
No. The primary endpoint was not significantly different; some secondary outcomes favored intravenous administration.
References & editorial record
- MedlinePlus · Oxytocin ↗
- Intramuscular versus intravenous oxytocin to prevent postpartum haemorrhage at vaginal delivery: randomised controlled trial. ↗
- SOARS-B · intranasal oxytocin · 2021 ↗
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
